InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.58
(
0.20%
)
US TECH 100
19,110.00
(
-0.51%
)
Dow Jones
39,553.22
(
1.03%
)
Brent Oil
84.72
(
0.83%
)
Bitcoin
61,141.86
(
-3.19%
)
Post# of 252316
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 217336

Friday, 05/25/2018 11:55:50 AM

Friday, May 25, 2018 11:55:50 AM

Post# of 252316
AZN—PACIFIC study in Stage-III NSCLC shows statsig OS benefit:

https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html

The HR for OS has not been disclosed, pending presentation at a medical conference.

The FDA approved AZN’s Imfinzi in Stage-III NSCLC in Feb 2018 (#msg-138626896) based on PACIFIC’s statsig PFS for chemo/Imfinzi (sequentially rather than in combination) vs chemo alone. Today is the first time PACIFIC’s OS outcome was reported.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up